Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Boosted by Wealthfront Advisers LLC

Wealthfront Advisers LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 68.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,990 shares of the biopharmaceutical company's stock after purchasing an additional 6,501 shares during the period. Wealthfront Advisers LLC's holdings in Regeneron Pharmaceuticals were worth $11,390,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of REGN. Rakuten Securities Inc. lifted its holdings in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the third quarter worth about $26,000. Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals in the third quarter worth about $39,000. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $28,000. Finally, Valley Wealth Managers Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $49,000. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a report on Wednesday, February 5th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. Citigroup cut their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Finally, Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an "outperform" rating and a $1,150.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $973.13.

Remove Ads

Regeneron Pharmaceuticals Stock Down 3.6 %

Shares of NASDAQ:REGN opened at $718.16 on Wednesday. The company has a fifty day moving average of $697.08 and a 200-day moving average of $842.19. The company has a market capitalization of $78.51 billion, a PE ratio of 18.76, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.